AI-Stem Cell Researcher, Co-Founder@CTO

Minjun Kang

Hello, I am Minjun Kang, CTO and Co-founder of NOAH’S FARM PTE. LTD. in Singapore, and a Ph.D. candidate in Medicine at Seoul National University, where I also earned my master’s degree summa cum laude as valedictorian.


My research was selected as one of the Top 5 Medical R&D projects in Korea (2025, KHIDI). I previously worked as a cardiovascular researcher at Seoul National University Hospital and hold a B.S. in Biomedical Sciences from CHA University. I also serve as a reviewer for Springer Nature journals and am a professional member of the American Heart Association (AHA).

AI, Stem Cell Researcher


  • -
    NOAH'S FARM PTE. LTD. (Singapore), Co-founder/CTO

    Noah's Farm is a deep-tech startup building the future of taste. We develop proprietary AI that chemically recreates the world's most beloved flavors—and invents entirely new ones—at the molecular level.—“N-Palette”—that predict and generate novel flavor molecules.

    Raised KRW 4 billion (Pre-seed) from Sazze Partners (Silicon Valley) and Company K Partners (Korea).


    https://www.noahs-farm.xyz/.

  • -
    Seoul National University Hospital (Korea), Researcher@Cardiovascular

    I worked in the Cardiac Differentiation Team of the Cardiovascular Laboratory at the Biomedical Research Institute, with a focus that bridges computer science and stem cell biology.

    In computer science, my research centers on Transformer-based generative AI to design novel ligands for G protein–coupled receptors (GPCRs)—one of the novel therapeutic target classes. By combining advanced Transformer architectures with drug discovery pipelines, I develop new ligand candidates with high potential for stem cell–based therapeutics.

    In stem cell biology, I specialize in advanced cardiac differentiation protocols for both mouse embryonic stem cells and human-induced pluripotent stem cells (iPSCs). My expertise extends to the preservation of pluripotent stem cells, the development of lentiviral overexpression vectors, and the creation of conditional knockout transgenic mice for cardiovascular research.

  • -
    Stealth Startup (Korea), Founder

    I founded a cultured meat company dedicated to promoting human health through sustainable foods. In 2022, the company was selected as a finalist in the National Development Project (Topic: Cultured Meat) organized by the Korean Chamber of Commerce and Industry.

Education


Seoul National University (Korea), Ph.D Candidate
-

Ph.D. Candidate in Medicine (PI: Hyun-Jai Cho)

a. Studied research on generative AI models for discovering heart-specific GPCR ligands.

b. Selected as Top 5 Medical R&D in Korea (2025)

c. Awarded the Full Tuition Ph.D Scholarship by the Kwanak Foundation of SNU

Seoul National University (Korea), M.S
-

Master of Medicine (PI: Hyo-Soo Kim)

a. Studied the mechanism of a GPCR with potential as a target for gene and stem cell therapies.

b. Graduated with highest honors in class, recognized for academic excellence. (Valedictorian)

c. Received the Excellent Thesis Honor.

CHA University (Korea), B.S
-

Bachelor of Science in Biomedical Science
a. Studied undergraduate research in stem cell biology.

b. Affiliated with Cha Medical Group.

Academic Activitiy

Reviewer

  • Q1 journals in the Agricultural and Biological Sciences field published by Springer Nature.

Member

  • AHA(American Heart Association) Professional Member

Research Interests

  • GPCR biology and ligand discovery

  • Cardiovascular regeneration and molecular signaling

  • Generative AI models in biomedical research

  • Translational applications of stem cell and AI-based therapeutics


Journals
-

  1. 1st Author

1.1 Minjun Kang, Choon-Soo Lee, HyunJu Son, Jeongha Lee, Jaewon Lee, Hyun Ju Seo, Moo-kang Kim, Murim Choi, Hyun-Jai Cho, and Hyo-Soo Kim. Latrophilin-2 deletion in cardiomyocyte disrupts cell junction, leading to D-CMP -Circulation Research (Top-Ranked Journal in cardiovascular(AHA Journal), IF 16.2 with a 5-year IF of 20.8, 2024)



  1. Co-Author


2.1 Jeehoon Kang, Hyun Ju Seo, HyunJu Son, Minjun Kang, Jaewon Lee, Eun Ju Lee, Hyun-Jai Cho, Hyo-Soo Kim. Newly-engineered angiopoietin-1 as a cell-priming agent for CVD - Cellular and Molecular Life Sciences (IF 6.2, 2025)


2.2 Jin-Woo Lee, Choon-Soo Lee, HyunJu Son, Jaewon Lee, Minjun Kang, Jinho Chai, Hyun-Jai Cho, Hyo-Soo Kim. SOX17-mediated LPAR4 expression plays a pivotal role in cardiac development and regeneration after myocardial infarction -Experimental & Molecular Medicine (IF 12.9, Nature Portfolio, 2023)


2.3 Choon-Soo Lee, Hyun-Jai Cho, Jin-Woo Lee, Hyun Ju Son, Jaewon Lee, Minjun Kang, Hyo-Soo Kim. The G Protein-Coupled Receptor Latrophilin-2, A Marker for Heart Development, Induces Myocardial Repair After Infarction -Stem Cell Translational Medicine (IF 6.94, 2022)


Google Scholar LINK
Honor
-

Top 5 Medical R&D among Korea’s Top 30 Healthcare Research in 2025 - KHIDI

Excellent Thesis Honor - Seoul National University, 2024

Excellent Paper Honor - Basic Science Society of the Korean Heart Association, 2024


Scholarship
-

Total USD 17,700
Full Tuition Ph.D Scholarship - the Gwanak Foundation of Seoul National University

BK21 Scholarship - Seoul National University

Interview


Biological Research Information Center, BRIC
-

BRIC Hanbitsa Interview

LINK

Press Release


NOAH'S FARM Pre-Seed
-

Raised KRW 4 billion (Pre-seed) from Sazze Partners (Silicon Valley) and Company K Partners (Korea).

LINK
Top 5 Medical R&D in 2025
-

By Ministry of Health and Welfare, Korea Health Industry Development Institute.

Link
Identified a novel mechanism
-

At Seoul National University Hospital (Korea)

Link
National Development Project
-

At Korea Chamber of Commerce and Industry (KCCI)

LINK

2025 Minjun Kang Copyright